Here, we investigated the therapeutic effect of IMMU, an FDA-approved ADC targeting TROP2, either alone or in combination with IACS, an oral and selective OXPHOS inhibitor, in advanced ESCC. Here, TACSTD2 is linked to esophageal squamous cell carcinoma.